Drug Trial Radar · NCT04361552
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Last checked: Nov 19, 2026Latest source record: Jun 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Apr 7, 2020
Primary completion
Jun 2, 2020
Study completion Jun 2, 2020
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Apr 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
Conditions
- Cerebrovascular Accident
- Chronic Obstructive Pulmonary Disease
- Chronic Renal Failure
- Coronary Artery Disease
- Diabetes Mellitus
- Malignant Neoplasm
- SARS Coronavirus 2 Infection
Interventions
Best PracticeOther
Receive standard of care
TocilizumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- 7-day length of invasive mechanical ventilation (MV)Time frame: Up to 7 days
- 30-day mortality rateTime frame: Up to 30-day after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.